2019 American Society of Hematology Annual Meeting*

Download All
December 7-10, 2019; Orlando, Florida
Review slidesets and analyses of key data from the 2019 Hematology meeting.

Nonmalignant Hematology

Capsule Summary Slidesets

Avatrombopag increases cumulative platelet response rate vs placebo in refractory chronic ITP.

Released: December 11, 2019

This ad hoc analysis found durable responses and multiple episodes of clinically meaningful reductions in transfusion dependence among patients with β-thalassemia receiving luspatercept.

Released: December 17, 2019

Interim results from the phase III Northstar-3 study showed that most patients with transfusion-dependent β-thalassemia who received betibeglogene autotemcel gene therapy produced sufficient HbAT87Q to stop RBC transfusions for ≥ 3 months.

Released: December 17, 2019

Early-stage data suggest rapid, durable activity of the novel Bruton tyrosine kinase inhibitor PRN1008 in heavily pretreated patients with relapsed/refractory ITP.

Released: December 10, 2019

Preliminary data showed that sutimlimab resulted in rapid and durable increase in platelet count in patients with multirefractory chronic ITP.

Released: December 18, 2019

First-in-class inhibitor of classical complement pathway demonstrates rapid and durable efficacy in cold agglutinin disease.

Released: December 15, 2019

Preliminary results from pilot feasibility study suggest that a gene therapy construct targeting BCL11A is safe, effectively induces HbF expression, and improves sickling signs and symptoms when delivered to patients with severe SCD.

Released: December 13, 2019
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings